Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Neuropathix Inc (OP: NPTX )

N/A UNCHANGED
Last Price Updated: 12:23 PM EDT, Oct 19, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0003
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on Profitability, Further Expansion
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Cannabis
Exposures Cannabis
Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS
The three-year $2.97 million Phase 2 STTR Study Grant through the NIH HEAL Initiative (Helping End Addiction Long-term) is providing funding specifically in the Development of KLS-13019 for Neuropathic... 
From Neuropathix, Inc.
Via AccessWire
Exposures COVID-19

Performance

More News

Read More
Medical Marijuana, Inc. Reports Revenue Of $7.8M For Q1 2022
Via Benzinga
Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019
From Neuropathix, Inc.
Via AccessWire
Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding
From Neuropathix, Inc.
Via AccessWire
Neuropathix, Inc. Welcomes Daniele Piomelli, PhD, MD to the Company’s Scientific Advisory Board
From Neuropathix, Inc.
Via AccessWire
Topics Cannabis Derivatives Intellectual Property
Exposures Cannabis Derivatives Intellectual Property
Neuropathix, Inc. Receives Patent Grant from India for Its Novel Anti-Inflammatory Compounds
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company's Over-The-Counter Cosmeceutical Assets
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company's Scientific Advisory Board
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders
From Neuropathix, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.